Ossium Health

Executive Summary

Ossium Health is a clinical-stage bioengineering company pioneering the recovery and banking of hematopoietic stem and progenitor cells (HSPCs) from deceased organ and tissue donors. Founded in 2016 and headquartered in Indianapolis, the company leverages this novel platform to address critical shortages in cell therapy sources for hematologic diseases, organ transplant rejection, and orthopedic conditions. By utilizing deceased donors, Ossium aims to provide an off-the-shelf, scalable supply of HSPCs that could expand access to life-saving treatments. Though clinical-stage, the company has not yet disclosed specific pipeline candidates or trial phases publicly.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical trial initiation for HSPC therapy in hematologic malignancies35% success
• TBDSeries B financing round to advance pipeline60% success
• Q2 2027FDA IND clearance for orthopedic application of HSPCs30% success